Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Francesca Ricci, Federica Guffanti, Giovanna Damia, Massimo Broggini

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts'. Together they form a unique fingerprint.

Medicine & Life Sciences